MedPath

Comparison of Polyethylene glycol 3350 and 4000 in children with chronic constipatio

Phase 3
Completed
Conditions
Health Condition 1: K590- Constipation
Registration Number
CTRI/2022/04/041995
Lead Sponsor
Dr SNIGDHA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
90
Inclusion Criteria

Duration of more than 4 weeks for all ages .

Presence of >=2 of the following :

1) Defecation frequency <=2 times per week

2) Fecal incontinence >=1 times per week after the acquisition of toileting skills ,

3) history of excessive stool retention ( retentive posture, stool witholding behaviour)

4) history of painful or hard bowel movements ,

5) presence of a large mass in the rectum or on per abdomen examination

6) history of large diameter stools that may obstruct the toilet.

Exclusion Criteria

(Based on History , Physical Examination and Exclusion of Red Flags)

1) Motility related disorders -Hirschprung disease

2) Congenital anomalies -Anal stenosis , anteriorly displaced Anus,spinal cord anomalies( tethered cord , spina bifida)

3) Devlopmental defect -mental retardation , autism OR cerebral palsy

4) use of PEG with 2 months before inclusion or concurrent use of other drugs influencing gastrointestinal motility -opiates, anticholinergic agents,phenobarbitone,vincristine.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Stool frequency per weekTimepoint: over the 24 weeks of treatment
Secondary Outcome Measures
NameTimeMethod
1)Stool consistency ( According to Bristol stool chart , Type 3 and beyond ) <br/ ><br>2)Frequency of pain or difficulty in passing stools <br/ ><br>(no of episodes per week ) <br/ ><br>3)Frequency of soiling episodes (no. of episodes per week) <br/ ><br>4)Compliance with the preparation ( 80% of the prescribed dose) <br/ ><br>5)side effects like nausea,diarrhea , abdominal pain <br/ ><br>6)use of any rescue therapyTimepoint: over the 24 weeks of treatment
© Copyright 2025. All Rights Reserved by MedPath